Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MG1-MAGEA3 + Ad-MAGEA3 + pembrolizumab + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Turnstone Biologics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Administration
- Intravenous, Intramuscular, Oral
01
Overview
This is a **combination therapy** consisting of two investigational cancer vaccines (**MG1-MAGEA3** and **Ad-MAGEA3**), the immune checkpoint inhibitor **pembrolizumab** (a PD-1 antagonist), and the chemotherapeutic agent **cyclophosphamide**. MG1-MAGEA3 and Ad-MAGEA3 are viral vector-based immunotherapies designed to induce an immune response against tumors expressing the MAGEA3 antigen. Pembrolizumab blocks the PD-1 receptor on T cells, thereby enhancing anti-tumor immune responses. Cyclophosphamide is a cytotoxic alkylating agent, often used here at low (metronomic) doses, partly to deplete regulatory T cells and further stimulate anti-tumor immunity. This combination aims to induce robust, antigen-specific tumor immunity and synergize with immune checkpoint inhibition for enhanced anti-cancer efficacy.
- Other names
- pembrolizumabcyclophosphamide
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)MAGEA3 (Melanoma-associated antigen 3)
Beyond the preview
Go deeper on MG1-MAGEA3 + Ad-MAGEA3 + pembrolizumab + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MG1-MAGEA3 + Ad-MAGEA3 + pembrolizumab + cyclophosphamide.